Compare WEST & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | LCTX |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.6M | 393.9M |
| IPO Year | N/A | N/A |
| Metric | WEST | LCTX |
|---|---|---|
| Price | $4.33 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.00 | $4.25 |
| AVG Volume (30 Days) | 625.7K | ★ 2.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,078,457,000.00 | $10,816,000.00 |
| Revenue This Year | $40.23 | N/A |
| Revenue Next Year | $8.80 | $176.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.89 | 24.05 |
| 52 Week Low | $3.59 | $0.37 |
| 52 Week High | $8.29 | $2.09 |
| Indicator | WEST | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 44.23 |
| Support Level | $4.00 | $1.66 |
| Resistance Level | $4.48 | $1.76 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 57.74 | 7.04 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider in the U.S, providing coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice and restaurant, convenience store and travel center, non-commercial account, CPG, and hospitality industries around the world. The company's segment includes Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.